Michael A Holinstat
Program Director
Pharmacology
Professor of Pharmacology
Professor of Internal Medicine
Professor of Surgery
Pharmacology
1150 West Medical Center Drive, 2220D Medical Sciences Research Building
Ann Arbor, MI 48109-5632
[email protected]

Available to mentor

Michael A Holinstat
Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • About

    Dr. Michael Holinstat is a professor in the department of pharmacology and a fellow of the American Heart Association. Dr. Holinstat’s research interests focus on understanding lipid, lipoxygenase, and oxygenase regulation of platelet signaling and function and how it relates to regulation of hemostasis and thrombosis. He serves as the inaugural Director of the Platelet Physiology and Pharmacology Platelet Core at the University of Michigan. Additionally, Dr. Holinstat serves on several national boards including the sub-committee on Hemostasis and Thrombosis at the American Society for Hematology and the Director for the NIH CTSI-funded T32 training grant in clinical research. Dr. Holinstat has received several national awards including the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the Council on Arteriosclerosis, Thrombosis, and Vascular Biology in 2012 and the Young Investigator Award in Structure-Function from the Eicosanoid Research Foundation in 2013. Dr. Holinstat has received numerous patents from the US, EU, and Japan patent offices for various therapeutic discoveries to treat cardiovascular disease. In addition to his NIH-funded research, Dr. Holinstat continues to translate his discoveries into potential clinical application through collaborations with Veralox Therapeutics, Cereno Scientific, and Lexicon Pharmaceuticals. Dr. Holinstat has published over 106 peer-reviewed publications in the area of platelet biology and lipids and his work is highly cited with an H-index of 41. Dr. Holinstat has spent the last 20 years training the next generation of clinical and translational scientists in the area of blood clotting, platelet biochemistry, and discovery of novel therapeutic approaches for treating thrombosis including undergraduates, graduate students, postdoctoral fellows, clinical fellows, and basic and clinical faculty.

    Links
    • Holinstat Lab Page
    Qualifications
    • Postdoctoral Research Fellow
      Vanderbilt University Medical Center, Pharmacology, 2008
    • PhD
      University of Illinois at Chicago, Chicago, 2004
    • MS
      University of Illinois at Chicago, Chicgao, 2000
    • BS
      Southern Connecticut State University, New Haven, 1995
    Center Memberships
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    • Center Member
      Caswell Diabetes Institute
    Research Overview

    Dr. Holinstat’s lab is studies various aspects of platelet function and thrombosis spanning studies in basic science, clinical investigations, as well as clinical trials in thrombotic risk in several at-risk populations. His studies current focus on several aspect of platelet regulation in hemostasis and thrombosis including 1) a clinical trial to determine novel approaches to limiting thrombosis in diabetes, 2) clinical research on thrombotic risk disparities by race, 3) oxylipin regulation of platelets, and 4) discovery of a first-in-human novel targets for preventing platelet activation and thrombosis including the discovery and development of several novel therapeutic drugs including 1) ML355 (also known as VLX-1005), a 12-lipoxygenase inhibitor developed by Dr. Holinstat’s lab that is currently in phase 2 clinical trials for the treatment of heparin-induced thrombocytopenia and thrombosis, and 2) CS585, a prostacyclin receptor agonist invented by Dr. Holinstat’s lab that is currently in preclinical development for treatment of a number of diseases including thrombosis.

    Recent Publications See All Publications
    • Journal Article
      Composition of thrombi in zebrafish: similarities and distinctions with mammals.
      Griffin MS, Dahlgren AR, Nagaswami C, Litvinov RI, Keeler K, Madenjian C, Fuentes R, Fish RJ, Neerman-Arbez M, Holinstat M, Adili R, Weisel JW, Shavit JA. J Thromb Haemost, 2023 Dec 30; DOI:10.1016/j.jtha.2023.12.025
      PMID: 38160724
    • Journal Article
      Antiplatelet strategies: past, present, and future.
      Stanger L, Yamaguchi A, Holinstat M. J Thromb Haemost, 2023 Dec; 21 (12): 3317 - 3328. DOI:10.1016/j.jtha.2023.09.013
      PMID: 38000851
    • Journal Article
      Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation.
      Banka AL, Guevara MV, Brannon ER, Nguyen NQ, Song S, Cady G, Pinsky DJ, Uhrich KE, Adili R, Holinstat M, Eniola-Adefeso O. Nat Commun, 2023 Apr 28; 14 (1): 2462 DOI:10.1038/s41467-023-37990-z
      PMID: 37117163
    • Journal Article
      Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design.
      La CC, Smith SA, Vappala S, Adili R, Luke CE, Abbina S, Luo HD, Chafeeva I, Drayton M, Creagh LA, de Guadalupe Jaraquemada-Peláez M, Rhoads N, Kalathottukaren MT, Henke PK, Straus SK, Du C, Conway EM, Holinstat M, Haynes CA, Morrissey JH, Kizhakkedathu JN. Nat Commun, 2023 Apr 26; 14 (1): 2177 DOI:10.1038/s41467-023-37709-0
      PMID: 37100783
    • Journal Article
      CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists
      Stanger L, Yalavarthi P, Lambert S, Rickenberg A, Goerger K, Gilmore D, Dahlof B, Bergh N, Holinstat M. Blood, 2023 Nov 28; 142 (Supplement 1): 1188 DOI:10.1182/blood-2023-186300
    • Journal Article
      HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding
      Stanger L, Holinstat M, Lambert S, Yalavarthi P, Bergh N, Dahlof B. Blood, 2023 Nov 28; 142 (Supplement 1): 1195 DOI:10.1182/blood-2023-186602
    • Journal Article
      Identification of the Role of SEL1L in Platelet Function with Implications for Atypical Equine Thrombasthenia in Thoroughbred Horses
      Dahlgren AR, Careddu F, Adili R, Kropp E, Li Q, Holinstat M, Biunno I, Balduini A, Shavit J, Tablin F, Finno CJ. Blood, 2023 Nov 28; 142 (Supplement 1): 3944 DOI:10.1182/blood-2023-187146
    • Journal Article
      Loss of 12-Lipoxygenase Improves the Post-Transfusion Function of Stored Platelets
      Larsen H, Byrne D, Ozpolat HT, Chauhan A, Bailey S, Rhoads N, Reed F, Stolla MC, Adili R, Holinstat M, Fu X, Stolla M. Blood, 2023 Nov 28; 142 (Supplement 1): 2668 DOI:10.1182/blood-2023-190021
    Featured News & Stories
    Department News
    Faculty Promotions (effective September 1, 2023)
    Faculty Promotions (effective September 1, 2023) at the U-M Medical School Department of Pharmacology
    Department News
    Congratulations to Dr. Holinstat: Cereno Scientific announces licensing agreement
    Congratulations to Dr. Holinstat at the U-M Medical School Department of Pharmacology, Cereno Scientific announces licensing agreement for drug candidate CS585.